Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143173 | 0.98 | AOC3 (0.48) | AOC3KDM4EALDH1A1TAAR1F13A1 | |
| SCHEMBL4120081 | 0.97 | AOC3 (0.51) | AOC3KDM4EALDH1A1TAAR1SMN1; SMN2 | |
| SCHEMBL490405 | 0.89 | AOC3 (0.53) | AOC3KDM4EALDH1A1TAAR1SMN1; SMN2 | |
| SCHEMBL27554389 | 0.88 | AOC3 (0.53) | AOC3KDM4EALDH1A1TAAR1SMN1; SMN2 | |
| SCHEMBL4426553 | 0.87 | POLB (0.42) | F13A1SMN1; SMN2POLBMAPK1LTB4R | |
| SCHEMBL6112724 | 0.86 | PPARA (0.52) | ALDH1A1MEN1KMT2AFFAR4LTB4R | |
| SCHEMBL6112796 | 0.85 | PPARA (0.55) | ALDH1A1F13A1MEN1KMT2AFFAR4 | |
| SCHEMBL612449 | 0.84 | FFAR4 (0.51) | KDM4EALDH1A1TAAR1MEN1KMT2A | |
| SCHEMBL6112741 | 0.82 | CTDSP1 (0.45) | ALDH1A1SMN1; SMN2MAPK1GAAMEN1 | |
| SCHEMBL11708826 | 0.81 | FFAR4 (0.44) | ALDH1A1SMN1; SMN2POLBMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100415719-C | 2, 5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | claimed |
| EP-1896391-B1 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | UNIV BAYLOR (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8394859-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2012068284-A2 | EFFICIENT METHOD FOR PREPARING FUNCTIONALIZED BENZOSUBERENES | BAYLOR UNIVERSITY (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120130129-A1 | Efficient Method for Preparing Functionalized Benzosuberenes | BAYLOR UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | BAYLOR UNIVERSITY | 2009-03-19 | — | — | US | disclosed |
| US-7429681-B2 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY (US) | 2008-09-30 | — | — | US | disclosed |
| CN-100415719-C | 2, 5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| EP-1896391-A2 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | Baylor University (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | BAYLOR UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
| WO-2006138427-A2 | COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY | BAYLOR UNIVERSITY (US) | 2006-12-28 | — | — | WO | disclosed |
| CN-1662504-A | 2, 5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2005-08-31 | — | — | CN | disclosed |
| EP-0426573-B1 | Phenoxypropylamine derivatives or salts thereof and antiulcer agents containing the same | TERUMO CORP (JP) | 1995-05-24 | — | — | EP | disclosed |
| US-5037837-A | 5-lipoxygenase inhibitor | TERUMO KABUSHIKI KAISHA (JP) | 1991-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130129-A1 | Efficient Method for Preparing Functionalized Benzosuberenes | CYP2B6, CYP2A6, GABRA6 | AOC3 1464/4885KDM4E 232/4885ALDH1A1 1302/4885 |
| US-20060293394-A1 | Combretastatin analogs with tubulin binding activity | TUBB, TUBB3, TUBB1 | AOC3 4712/4885KDM4E 4221/4885ALDH1A1 4033/4885 |
| US-20090075943-A1 | Combretastatin Analogs with Tubulin Binding Activity | TUBB, TUBB3, TUBB1 | AOC3 4712/4885KDM4E 4221/4885ALDH1A1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.